Dr. Rayan Al Jurdi has been a trailblazer in new forms of psychoneurological, neuropharmacological and neurological research. He has also been instrumental in bridging the gap between research initiatives and implementation in a patient setting. His work with ketamine treatment has helped bring effective methods beyond experiments into actual clinical use, helping patients find relief in novel ways. Dr. Al Jurdi’s interests go beyond medicine into pushing state of the art patient care models, and his biggest desire is for he and his colleagues to have a more direct impact on patients’ care. His research focuses on the psychopharmacology of treatment resistant mood disorder, including the clinical use of ketamine, late life depression, bipolar disorder, genetics of mental illness and transcranial magnetic stimulation. He has been the recipient of multiple awards in clinical care, teaching and research.